Chemical Works of Gedeon Richter Plc (RGEDF)
40.70
-0.45
(-1.10%)
USD |
OTCM |
Nov 13, 16:00
Chemical Works of Gedeon Richter Enterprise Value : 6.503B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 6.503B |
| November 12, 2026 | 6.586B |
| November 11, 2026 | 6.262B |
| November 10, 2026 | 6.324B |
| November 09, 2026 | 6.372B |
| November 06, 2026 | 6.284B |
| November 05, 2026 | 6.511B |
| November 04, 2026 | 6.553B |
| November 03, 2026 | 6.382B |
| November 02, 2026 | 6.441B |
| October 30, 2026 | 6.146B |
| October 29, 2026 | 6.551B |
| October 28, 2026 | 5.880B |
| October 27, 2026 | 6.564B |
| October 26, 2026 | 6.594B |
| October 23, 2026 | 6.456B |
| October 22, 2026 | 6.269B |
| October 21, 2026 | 6.269B |
| October 20, 2026 | 6.343B |
| October 19, 2026 | 6.307B |
| October 16, 2026 | 6.231B |
| October 15, 2026 | 6.124B |
| October 14, 2026 | 6.007B |
| October 13, 2026 | 6.109B |
| October 12, 2026 | 6.076B |
| Date | Value |
|---|---|
| October 09, 2026 | 5.848B |
| October 08, 2026 | 5.596B |
| October 07, 2026 | 5.642B |
| October 06, 2026 | 6.109B |
| October 05, 2026 | 5.995B |
| October 02, 2026 | 6.075B |
| October 01, 2026 | 6.083B |
| September 30, 2026 | 6.216B |
| September 29, 2026 | 6.242B |
| September 28, 2026 | 6.270B |
| September 25, 2026 | 6.393B |
| September 24, 2026 | 6.247B |
| September 23, 2026 | 6.279B |
| September 22, 2026 | 6.658B |
| September 21, 2026 | 6.819B |
| September 18, 2026 | 6.664B |
| September 17, 2026 | 6.748B |
| September 16, 2026 | 6.499B |
| September 15, 2026 | 6.348B |
| September 14, 2026 | 6.501B |
| September 11, 2026 | 6.365B |
| September 10, 2026 | 6.653B |
| September 09, 2026 | 6.594B |
| September 08, 2026 | 6.596B |
| September 04, 2026 | 6.729B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 598.40B |
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
| Veru, Inc. | 12.53M |
| Avadel Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 227.01M |
| Revenue (Quarterly) | 743.72M |
| Total Expenses (Quarterly) | 517.07M |
| EPS Diluted (Quarterly) | 1.238 |
| Gross Profit Margin (Quarterly) | 67.15% |
| Profit Margin (Quarterly) | 30.52% |
| Earnings Yield | 10.17% |
| Operating Earnings Yield | 14.03% |
| Normalized Earnings Yield | 10.17 |